Podcast Episodes
Back to SearchOncologists Overtreat Patients at End of Life
When it comes to end-of-life care for patients with cancer, “I think that there is a real deficit in
our training,” says Nathan I. Cherny, MD, direc…
1 year, 2 months ago
FDA Approvals Change Practice for Metastatic Breast Cancer With PIK3CA Mutations
Recent advances in hormone receptor–positive, HER2-negative metastatic breast cancer have led to questions about the timing of genetic testing and th…
1 year, 3 months ago
To Help Oncologists’ Burnout, Should Primary Care Take on More Burden?
The European Society for Medical Oncology (ESMO) Resilience Task Force recently released
recommendations intended to reduce burnout in oncology worl…
1 year, 4 months ago
Choosing Between an “Old Friend” and New Ones in EGFR-Mutated Metastatic NSCLC
When it comes to the treatment of EGFR-mutated metastatic non-small cell lung cancer (NSCLC), osimertinib (Tagrisso) is an “old friend,” says Kamya S…
1 year, 4 months ago
Privatization of Cancer Clinical Research Raises Concerns for Practice
Season 1 Episode 1
“Cancer clinical research has been largely privatized,” explains Joseph Unger, PhD, MS, associate
professor in the cancer prevention program at the …
1 year, 4 months ago
What 3 Big Trials Mean for Breast Cancer Practice
Treatment approaches for patients with hormone receptor (HR)-positive, HER2-negative breast cancer have rapidly evolved, thanks in part to data from …
1 year, 5 months ago
“Confusing for All of Us”: Questions Arise Over ADCs, HER2 in Metastatic Breast Cancer
Approvals of antibody-drug conjugates (ADCs) for metastatic breast cancer have introduced complex questions about HER2 expression. “It’s certainly be…
1 year, 5 months ago
”Where Do We Go From Here?” Targeted Therapies Lead to Challenging Choices in Breast Cancer
Newly approved targeted therapies for patients with advanced hormone
receptor (HR)-positive, HER2-negative breast cancer are changing care. “We
hav…
1 year, 6 months ago
After Practice Change in Unresectable Stage III NSCLC, Questions Remain
Data on the use of durvalumab after chemoradiotherapy transformed the standard of care for patients with unresectable stage III non-small cell lung c…
1 year, 7 months ago
What ”Incredibly Dramatic” Data on Osimertinib in NSCLC Mean for Practice
Results of the phase 3 LAURA clinical trial, presented at the 2024 American Society of Clinical Oncology Annual Meeting, showed that osimertinib sign…
1 year, 7 months ago